Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

ByConnor Hodde

Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121.  KPI-121 achieved statistical significance for the primary sign endpoint of bulbar conjunctival hyperemia, and promising trends were observed for key symptom endpoints. “The achievement of statistical significance for the primary sign endpoint in this relatively small trial is an extremely important accomplishment,” said Kim Brazzell, PhD, Chief Medical Officer of Kala.

Read the entire article here

Similar Posts

Transplanted Rod Precursor Cells Restore Vision in Experimental Mice

ByConnor Hodde

Studies in mouse models of night blindness have demonstrated that vision can be restored by transplanting rod precursor cells taken from mouse neonates directly into the retina of recipient animals. The University College London (UCL) Institute of Ophthalmology-led team showed that the transplanted rod cells made synaptic connections with the existing retinal circuitry, were light…

New drug candidate is promising therapeutic option for angiogenic retinal diseases

ByConnor Hodde

A research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal…

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

ByConnor Hodde

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…

Cause of inflammation in diabetes identified

ByConnor Hodde

Inflammation is one of the main reasons why people with diabetes experience heart attacks, strokes, kidney problems and other, related complications. Now, in a surprise finding, researchers at Washington University School of Medicine in St. Louis have identified a possible trigger of chronic inflammation.  Through a series of experiments in the animals and in cell…

Flexible Adult Stem Cells, Right There in Your Eye

ByConnor Hodde

Researchers reporting in the January issue of Cell Stem Cell, a Cell Press publication, have identified adult stem cells of the central nervous system in a single layer of cells at the back of the eye. That cell layer, known as the retinal pigment epithelium (RPE), underlies and supports photoreceptors in the light-sensitive retina. Without…

American Health Assistance Foundation Announces Latest Grants to Advance Promising Vision Research

ByConnor Hodde

  The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world….